Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: cyclin-dependent kinase inhibitors - Astex Therapeutics

Drug Profile

Research programme: cyclin-dependent kinase inhibitors - Astex Therapeutics

Alternative Names: AT 9311; AT1772; AT2035; AT3424; AT381; AT3851; LCQ 195; NVP-LCQ195

Latest Information Update: 25 Jul 2011

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Astex Therapeutics
  • Class Small molecules
  • Mechanism of Action CDC2 protein kinase inhibitors; Cyclin-dependent kinase 2 inhibitors; Mitosis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 06 Dec 2005 AT 9311 has been licensed to Novartis worldwide
  • 12 Sep 2005 AT 7519 has advanced from this programme into clinical development
  • 29 Nov 2004 Data presented at the British Cancer Research Meeting 2004 (BCRM 2004) have been added to the pharmacokinetics and Cancer pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top